Related Experiment Video

Updated: Jul 15, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

[Still no evidence on the efficacy of immunomodulatory therapy in reducing functional impairment in multiple

M Vermeulen1

  • 1Academisch Medisch Centrum/Universiteit van Amsterdam, afd. Neurologie, Postbus 22.660, II00 DD Amsterdam.. m.vermeulen@amc.uva.nl

Nederlands Tijdschrift Voor Geneeskunde
|May 3, 2007
PubMed

Insights

Immunomodulatory therapy helps prevent multiple sclerosis (MS) relapses in the first year. Further research is needed to determine if it reduces long-term disability from axonal degeneration.

Area of Science:

  • Neuroimmunology
  • Clinical Neurology

Background:

  • Immunomodulatory therapies are standard for multiple sclerosis (MS), reducing first-year relapse rates by 30%.
  • The long-term efficacy of these therapies on disability progression, primarily due to axonal degeneration, remains uncertain.
  • Relapse in MS is driven by inflammation impacting central nervous system conduction.

Discussion:

  • The study questions the benefit of current immunomodulatory therapy on axonal degeneration, a key driver of MS disability.
  • It highlights the need to assess if immunosuppression can mitigate disability progression before considering high-risk treatments like natalizumab.

Key Insights:

  • First-year relapse reduction by immunomodulatory therapy is established.
  • The impact of immunomodulatory therapy on MS-related axonal degeneration and long-term disability is currently unknown.
  • Determining the effect on disability is crucial for treatment decisions, especially before escalating to natalizumab.

Outlook:

  • Further clinical studies are required to evaluate the efficacy of immunomodulatory therapy in preventing axonal degeneration in MS.
  • This research will inform treatment strategies, potentially optimizing patient outcomes and guiding the use of advanced therapies.
  • Understanding the long-term benefits is essential for managing progressive disability in multiple sclerosis.

More Related Videos

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...